Non-specific immunoadsorption in patients with dilated cardiomyopathy: Mechanisms and clinical effects

Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy

“…As cardiodepressant antibodies belong to the IgG3 subgroup, previous studies have underlined the importance of adequate IgG3 reduction [32]. Despite application of a therapeutic protocol for optimized IgG3 reduction [5], in this pilot study, an IgG3 reduction of 58.5% was obtained, which is slightly lower compared to the previously described IgG3 reduction of 61-70% [33][34][35].…”

Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy

“…As cardiodepressant antibodies belong to the IgG3 subgroup, previous studies have underlined the importance of adequate IgG3 reduction [28]. Because of the application of a therapeutic protocol for optimized IgG3 reduction [5], an IgG3 reduction of 66.7% was obtained, which is higher than observed in previous pilot studies [10] and is in line with previously described IgG3 reduction of 61-70% [29][30][31].…”

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

“…Aged Pdcd1 -/mice develop lupus-like glomerulonephritis and arthritis on a C57BL/6 background, while they develop dilated cardiomyopathy (DCM) by generation of anti-troponin I antibodies on the BALB/c background 3,33 . This observation was the first clear experimental demonstration of autoimmune basis of DCM, and provided the rationale for immuno-adsorption therapy to this deadly disease 34 . The tissue-damaging autoantibodies produced in BALB/c-Pdcd1 -/mice require class switching and/or somatic hypermutation, because DCM and gastritis development in these mice is dependent on a cytidine deaminase AID, a master regulator of class switching and somatic hypermutation 30 .…”